Skip to Main Content

Paper Details

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial.
Nat Commun
34
2021
DM1, HER2, HER2+, HER2+ breast cancer, HER2+ tumors, T, T-DM1, TH, THP, breast cancer, cyclophosphamide, doxorubicin, early breast cancer, paclitaxel, patients, pertuzumab, stage II/III, trastuzumab, women
Author NameAffiliation
Christina YauUniversity of California San Francisco
Christina YauUniversity of California San Francisco
Denise M WolfUniversity of California San Francisco
Emanuel F PetricoinGeorge Mason University
Emanuel F PetricoinGeorge Mason University
Laura J Van't VeerUniversity of California San Francisco
Claudine IsaacsGeorgetown University
Judy C BougheyMayo Clinic
Rachel L YungUniversity of Washington
Rita NandaUniversity of Chicago
Teresa HelstenUniversity of California San Diego
Melissa Paoloni
Melissa Paoloni
Scott M Berry
Richard B SchwabUniversity of California San Diego
William F SymmansMD Anderson Cancer Center
Donald A Berry
  • 1 - 17

Datasets

Release 1.2